Safety and effectiveness of crizotinib, ceritinib, erlotinib, and gefitinib in patients with non-small cell lung cancer in real world
Latest Information Update: 29 Sep 2022
At a glance
- Drugs Crizotinib (Primary) ; Ceritinib; Erlotinib; Gefitinib
- Indications Lung cancer; Non-small cell lung cancer
- Focus Adverse reactions
- 28 Aug 2022 Results of Validation of Safety Outcomes , presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
- 21 Sep 2017 New trial record
- 30 Aug 2017 Trial design presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management.